The examination of the efficacy by adverse reaction changing the treatment with Oxybutynin or Mirabegron on the patient who cannot go on treatment with anticholinergic agent

Trial Profile

The examination of the efficacy by adverse reaction changing the treatment with Oxybutynin or Mirabegron on the patient who cannot go on treatment with anticholinergic agent

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Nov 2015

At a glance

  • Drugs Mirabegron (Primary) ; Oxybutynin
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top